Trial Profile
A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Vincristine (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 23 Jan 2023 Status changed to recruiting.
- 08 Jun 2022 Planned End Date changed from 30 Apr 2021 to 31 Dec 2028.
- 08 Jun 2022 Planned primary completion date changed from 30 Apr 2021 to 31 Dec 2028.